BlackRock’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-7,199,683
| Closed | -$24.5M | – | 5131 |
|
|
2018
Q3 | $24.5M | Buy |
7,199,683
+586,238
| +9% | +$2.11M | ﹤0.01% | 2755 |
|
|
2018
Q2 | $24.9M | Buy |
6,613,445
+534,831
| +9% | +$2.6M | ﹤0.01% | 2738 |
|
|
2018
Q1 | $24.9M | Sell |
6,078,614
-19,334
| -0.3% | -$90K | ﹤0.01% | 2644 |
|
|
2017
Q4 | $28.4M | Buy |
6,097,948
+112,381
| +2% | +$619K | ﹤0.01% | 2603 |
|
|
2017
Q3 | $42.5M | Buy |
5,985,567
+579,741
| +11% | +$4.17M | ﹤0.01% | 2378 |
|
|
2017
Q2 | $39.1M | Sell |
5,405,826
-9,505
| -0.2% | -$59.4K | ﹤0.01% | 2404 |
|
|
2017
Q1 | $33.4M | Buy |
5,415,331
+5,408,594
| +80,282% | +$29.6M | ﹤0.01% | 2452 |
|
|
2016
Q4 | $40K | Sell |
6,737
-1,246
| -16% | -$6.81K | ﹤0.01% | 3041 |
|
|
2016
Q3 | $42K | Hold |
7,983
| – | – | ﹤0.01% | 3053 |
|
|
2016
Q2 | $53K | Buy |
7,983
+1,860
| +30% | +$10.4K | ﹤0.01% | 2910 |
|
|
2016
Q1 | $28K | Buy |
6,123
+3,746
| +158% | +$15K | ﹤0.01% | 2679 |
|
|
2015
Q4 | $12K | Hold |
2,377
| – | – | ﹤0.01% | 2825 |
|
|
2015
Q3 | $8K | Hold |
2,377
| – | – | ﹤0.01% | 2857 |
|
|
2015
Q2 | $24K | Hold |
2,377
| – | – | ﹤0.01% | 2315 |
|
|
2015
Q1 | $30K | Hold |
2,377
| – | – | ﹤0.01% | 2174 |
|
|
2014
Q4 | $34K | Hold |
2,377
| – | – | ﹤0.01% | 2125 |
|
|
2014
Q3 | $33K | Hold |
2,377
| – | – | ﹤0.01% | 2117 |
|
|
2014
Q2 | $36K | Sell |
2,377
-655
| -22% | -$9.29K | ﹤0.01% | 2088 |
|
|
2014
Q1 | $51K | Buy |
3,032
+922
| +44% | +$13.9K | ﹤0.01% | 1916 |
|
|
2013
Q4 | $27K | Hold |
2,110
| – | – | ﹤0.01% | 2213 |
|
|
2013
Q3 | $21K | Hold |
2,110
| – | – | ﹤0.01% | 2267 |
|
|
2013
Q2 | $16K | Buy |
+2,110
| New | +$16.5K | ﹤0.01% | 2421 |
|
BlackRock's KERX Position: Q4 2018 in Review
BlackRock sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 7,199,683 shares — an estimated $24.5M sold.
BlackRock first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $42.5M in Q3 2017. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- BlackRock reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- BlackRock sold 7,199,683 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $24.5M.
- BlackRock first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- BlackRock's Keryx Biopharmaceuticals Inc position peaked at $42.5M in Q3 2017.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on BlackRock's 13F filing for Q4 2018, filed 8 Feb 2019.